Market
What will be the annual sales of HS-10535 by end of 2027?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Merck's financial reports and market analysis reports
Story
Merck Licenses Oral GLP-1 Drug from Hansoh Pharma for Potential Cardiometabolic Benefits in $2 Billion Deal
Dec 18, 2024, 12:15 PM
Merck & Co. Inc. has entered into an exclusive global license agreement with Hansoh Pharma, a Chinese biopharmaceutical company, for the development, manufacture, and commercialization of HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. The agreement includes an upfront payment of $112 million to Hansoh Pharma, with the potential for up to $1.9 billion in milestone payments and royalties on sales. Merck aims to leverage this deal to enhance its pipeline in cardiometabolic diseases, focusing on the potential of HS-10535 to provide cardiometabolic benefits beyond weight reduction. The transaction reflects Merck's strategy to augment its offerings in the growing obesity drug market, which is expected to reach over $100 billion annually by the early 2030s.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Phase 1 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Phase 2 completion • 25%
Joint Venture • 25%
Merck • 25%
Hansoh Pharma • 25%
Other • 25%
Decrease by 0-10% • 25%
Increase by 0-10% • 25%
Decrease by over 10% • 25%
Increase by over 10% • 25%
Other • 25%
European Union • 25%
United States • 25%
China • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
Above 35 trillion yen • 25%
25 to 30 trillion yen • 25%
30 to 35 trillion yen • 25%
Below 25 trillion yen • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
More than $200 million • 25%
$100 million to $200 million • 25%
30% to 39% • 25%
Less than 20% • 25%
20% to 29% • 25%
40% or more • 25%
27-30 trillion yen • 25%
Less than 25 trillion yen • 25%
More than 30 trillion yen • 25%
25-27 trillion yen • 25%